88 results about "Bacillus perfringens" patented technology

The invention discloses a method for improving the fermentation performance of clostridium aerovorans and application of the clostridium aerovorans, and according to the method, an effective amount of methionine or a derivative thereof is added into a fermentation culture medium of the clostridium aerovorans to completely replace expensive complex organic nitrogen sources such as yeast extracts. The method successfully solves the three technical bottlenecks of slow biomass accumulation, low ethanol yield and dependence on expensive nitrogen sources in the fermentation process of the clostridium aerovorans by utilizing synthesis gas or CO2 / H2 mixed gas. Experiments prove that methionine or a derivative thereof can synergistically promote growth metabolism of thalli and a synthesis path of a product, so that the gas conversion efficiency of a carbon source is remarkably improved and metabolism is guided to flow to ethanol synthesis while the growth rate and the final biomass of the thalli are improved, and thus the production capacity of alcohols is synchronously enhanced. The method is simple in process and remarkable in effect, and an efficient and economical new strategy is provided for reducing the production cost of biofuel and promoting industrial application of a synthesis gas biorefinery technology.

The invention discloses saccharomyces boulardii, a culture and a preparation method and application of the saccharomyces boulardii. The preservation number of the strain is CCTCC (China Center for Type Culture Collection) NO: M 20252633. The preparation method comprises the following steps: preparing saccharified liquid by taking white spirit vinasse or brewer's grains as a main raw material and adopting a high-temperature alkali treatment and composite enzymolysis process, inoculating strains for liquid-state high-density fermentation, carrying out solid-liquid separation on fermentation liquor, taking a liquid phase, and carrying out spray drying. According to the method, high-value utilization of the waste vinasse is realized, and the production cost is remarkably reduced. The obtained culture is rich in viable bacteria and active small peptides, and has the characteristics of strong tolerance, wide antibacterial spectrum and the like. As a feed additive, the feed additive can effectively reduce the diarrhea rate of piglets, inhibit clostridium perfringens and prawn vibrios of broilers, and improve the oxidation resistance and production performance of animals.

The invention relates to the technical field of biological medicine, in particular to a composition for blocking formation of phage treatment tolerance and application of the composition. The composition comprises a folium ilicis purpurea ethyl acetate extraction active component and a clostridium perfringens specific bacteriophage, the folium ilicis purpurea ethyl acetate extraction active component is prepared from the following components in percentage by mass: 8 to 15 percent of protocatechuic acid and 5 to 10 percent of ethyl gallate, and the mass ratio of the protocatechuic acid to the ethyl gallate is (1.5 to 1) to (2.5 to 1); the clostridium perfringens specific bacteriophage is a virulent bacteriophage capable of specifically cracking a clostridium perfringens NetB toxin positive strain. According to the invention, the shallow thought that the existing compounding technology only pursues synergistic sterilization is subverted, and a deep synergistic mode of bacteriophage splitting attack and folium ilicis purpurea component disintegration bacterial defense program is proposed and verified for the first time. And the formation of tolerance is fundamentally blocked, so that a more thorough and more lasting treatment effect is realized, and the comprehensive production performance of animals is accidentally and greatly improved on the basis of the treatment effect.

The invention relates to the technical field of intestinal pathogen detection, in particular to a multiplex PCR (polymerase chain reaction) primer group, a kit and a method for detecting pathogens causing calf diarrhea. The invention provides a primer group for detecting diarrheagenic Escherichia coli eaeA, stx1 and stx2 virulence genes, clostridium perfringens and cryptosporidium, and a multiple PCR (Polymerase Chain Reaction) method for detecting the diarrheagenic Escherichia coli eaeA, stx1 and stx2 virulence genes, clostridium perfringens and cryptosporidium is established on the basis of the primer group. According to the primer group and the multiple PCR method disclosed by the invention, the mixed infection and single infection conditions of diarrheogenic Escherichia coli eaeA, stx1 and stx2 virulence genes, clostridium perfringens and cryptosporidium in a sample to be detected can be determined through one-time multiple PCR reaction, and compared with a common PCR method, the primer group and the multiple PCR method are more convenient and quicker, and time and resources are saved; and compared with real-time fluorescent quantitative PCR, the method is more cost-saving and convenient to operate.

The invention belongs to the technical field of gene engineering, and particularly relates to recombinant lactobacillus for expressing clostridium perfringens multiple antigens of targeted dendritic cells as well as a construction method and application of the recombinant lactobacillus. The recombinant lactobacillus contains an expression vector for expressing a fusion gene; the fusion gene comprises sequences for coding and expressing a PgsA '-fimA fusion protein, a LysM-Fba fusion protein, an LP1261-NetB fusion protein, a phi54 targeting element and a Pas escape element; a sequence for coding the PgsA '-fimA fusion protein is shown as SEQ ID NO: 1, a sequence for coding the LysM-Fba fusion protein is shown as SEQ ID NO: 2, and a sequence for coding the LP1261-NetB fusion protein is shown as SEQ ID NO: 3. When the recombinant lactobacillus is used for immunizing animals, mucosal immunity, cellular immunity and humoral immunity reactions can be induced, the immunocompetence of organisms can be comprehensively enhanced, and the recombinant lactobacillus can be used for preparing oral vaccines for prevention and control of chicken necrotic enteritis.

The invention relates to a novel bacillus subtilis (B.subtilis) with a strong inhibition effect on clostridium perfringens (C. perfringens), and an application of the bacillus subtilis as a probiotic.

The invention relates to bacillus velezensis Bv-GD2 and application of the bacillus velezensis Bv-GD2. The classification name of the bacillus velezensis Bv-GD2 is bacillus velezensis, and the preservation number of the bacillus velezensis Bv-GD2 is GDMCC No: 66722. The strain is wide in antibacterial spectrum and high in tolerance, has the enzyme production capacity and the antibacterial active substance production capacity, and can remarkably inhibit common intestinal pathogens such as clostridium perfringens, salmonella, staphylococcus aureus and escherichia coli, relieve intestinal lesions, improve the health degree of the intestinal environment and improve the growth performance of livestock and poultry.

This invention belongs to the field of biotechnology and discloses a monoclonal antibody that specifically binds to the recombinant protein of Clostridium perfringens (Cp) β2 toxin, a hybridoma cell line, and its applications. This invention provides a monoclonal antibody that specifically binds to the β2 toxin protein and a hybridoma cell line CPB2-2A4 (accession number CCTCC NO: C2024312) that secretes this monoclonal antibody. The monoclonal antibody reacts only with the Cp β2 toxin protein and does not cross-react with other pathogens infecting cattle and sheep, exhibiting extremely high specificity. The kit utilizes competitive ELISA technology, using a mouse monoclonal antibody that specifically binds to the Cp β2 toxin recombinant protein as a competing antibody, enabling the detection of Cp β2 toxin antibodies in serum from various animal sources, avoiding species limitations of sample sources. Furthermore, the kit exhibits good reproducibility. The kit has relatively relaxed technical requirements during operation and can be widely used in production for applications such as Cp epidemiological surveys and vaccine immunization level monitoring.

The invention provides a kit for detecting multiple piglet diarrhea pathogens and a detection method, and belongs to the technical field of biological information detection. The kit comprises a reaction reagent, wherein the reaction reagent comprises a porcine epidemic diarrhea virus specific primer and a probe, a porcine delta coronavirus specific primer and a probe, a piglet pathogenic escherichia coli specific primer and a probe, a clostridium perfringens specific primer and a probe, a buffer solution, an enzyme mixed solution and a freeze-drying protective additive. The detection method adopts the kit for detecting various piglet diarrhea pathogens. According to the kit disclosed by the invention, simultaneous detection of four target genes including the porcine epidemic diarrhea virus, the porcine delta coronavirus, the piglet pathogenic escherichia coli and the clostridium perfringens can be realized only through one-time amplification, so that the detection time is greatly shortened while the detection cost is reduced; the kit has extremely high specificity, sensitivity and repeatability, and the primers and the probes do not interfere with each other; good normal-temperature storage stability is also realized.

The invention discloses bacillus velezensis LYBV022 and application thereof in preparation of a preparation for inhibiting clostridium perfringens infection, and belongs to the technical field of microorganisms. The invention discloses a bacillus velezensis LYBV022, and the preservation number of the bacillus velezensis LYBV022 is GDMCC No: 66952. The bacillus velezensis LYBV022 disclosed by the invention has a relatively good antibacterial ability on clostridium perfringens, staphylococcus aureus, escherichia coli and the like, so that the bacillus velezensis LYBV022 has a clinical application potential.

The utility model relates to a clostridium perfringens rapid detection reagent box, and relates to the field of detection reagent boxes. The device comprises a main box shell, a middle partition plate is installed in the main box shell, a first partition plate and a second partition plate are installed in the middles of the two sides of the middle partition plate respectively, and the first partition plate and the second partition plate are both fixedly connected with the middle partition plate in a sealed mode; the space of the main box shell is divided into a reaction area, a cooling area, a material area and a sample storage area by the middle partition plate, the first partition plate and the second partition plate, and a box cover capable of being turned over to be opened is further mounted on the upper end face of the main box shell. Through reasonable partition design, the functions of reaction, cooling, material storage, sample preservation and the like are integrated in one reagent box, so that the detection process is more ordered, and the detection efficiency is improved. The ultraviolet lamp and the heating lamp are arranged, so that the disinfection, sterilization and temperature control functions can be realized, various requirements in the detection process are met, and the accuracy and the reliability of a detection result are improved.

The application discloses a broad-spectrum bacteriostatic Clostridium subsp. and a preparation method and application thereof, and belongs to the technical field of microorganisms. The strain is named as DMS028, is preserved in the China General Microbiological Culture Collection Center, and has a preservation number of CGMCC No. 38049. The strain has broad-spectrum bacteriostatic activity, can simultaneously inhibit gram-negative bacteria Aeromonas hydrophila in aquaculture, gram-positive bacteria Clostridium perfringens in livestock and poultry breeding, and plant diseases such as Exserohilum longipes and Fusarium oxysporum, and overcomes the defects of narrow bacteriostatic spectrum of existing microbial preparations. The preparation method adopts two-stage temperature anaerobic culture, and adds lysine methyl ester, leucine ethyl ester, palmitoyl glycine and lauroyl arginine ethyl ester as an antibacterial substance synergist and a stabilizer, and has the advantages of simple process, convenient operation, no need of complex equipment, easy scale production, efficient high-activity bacterial body and antibacterial product.

The application discloses antagonistic Bacillus of Clostridium perfringens type G and application, the Bacillus is Bacillus sonorensis CB-6, and is classified and named as Bacillus sonorensis CB-6, the preservation number is CCTCC NO: M20251373, the preservation date is June 12, 2025, and the preservation unit is China Center for Type Culture Collection, which is located at Wuhan University, No. 299, Bayi Road, Wuchang District, Wuhan City, Hubei Province.The sterile fermentation supernatant of Bacillus sonorensis CB-6 provided by the application has neutral pH value, can inhibit Clostridium perfringens with high activity, the bacteriostatic effect is not dependent on organic acid such as lactic acid, the bacteriostatic effect is significant and stable, can significantly enhance the immunity of laying hens after Clostridium perfringens infection and improve the egg production rate, and solves the problem that laying hens are prone to necrotic enteritis during the egg production period and are not suitable for using antibiotics for prevention and control.

The application belongs to the field of biological products, and relates to a single-domain antibody of epsilon toxin of Clostridium perfringens and application thereof. The application specifically discloses a single-domain antibody of epsilon toxin of Clostridium perfringens, and the amino acid sequence of the single-domain antibody is shown in SEQ ID NO. 16. The single-domain antibody can neutralize epsilon toxin in vivo, can treat animals poisoned by epsilon toxin, and has application prospect.

The application relates to the technical field of biological medicine, and discloses application of maslinic acid or a derivative thereof in preparation of a product for treating Clostridium perfringens infection. The application verifies that the maslinic acid has a good inhibiting effect on Clostridium perfringens through in-vitro experiments and in-vivo infection models, and has a good treatment effect on intestinal infection of Clostridium perfringens in mammals and avian necrotic enteritis, thereby providing a new approach and thought for treatment of Clostridium perfringens infection, and having important clinical significance and application value.

The application belongs to the technical field of biotechnology, and particularly relates to a Clostridium perfringens bacteriophage lytic enzyme produced by Bacillus subtilis, a preparation method and application thereof, an optimized Clostridium perfringens bacteriophage lytic enzyme coding nucleic acid sequence according to the codon bias of Bacillus subtilis, and an optimized Clostridium perfringens bacteriophage lytic enzyme coding nucleic acid sequence as shown in SEQ ID NO. 1. The preparation method of the Clostridium perfringens bacteriophage lytic enzyme is as follows: firstly, a recombinant expression vector containing a Clostridium perfringens bacteriophage lytic enzyme gene is constructed, and then the vector is transferred into a Bacillus subtilis competent cell to obtain a Bacillus subtilis strain recombinant engineering bacterium. After the recombinant strain is induced to express, a fermentation liquor with Clostridium perfringens bacteriophage lytic enzyme activity can be obtained. The fermentation liquor can specifically inhibit the growth of Clostridium perfringens, and provides a safe, efficient and orally-taken preparation for treating animal diseases caused by Clostridium perfringens.

The invention belongs to the technical field of biology, and particularly relates to a bactrian camel clostridium perfringens AD type bivalent inactivated vaccine as well as a preparation method and application thereof. The invention relates to a bactrian camel clostridium perfringens AD type bivalent inactivated vaccine, the bivalent inactivated vaccine comprises two inactivated strain antigens, and the antigens are a bactrian camel A type aerogenic bacteria clostridium perfringens strain with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.35194 and a double hump D type aerogenic bacteria clostridium perfringens strain with the preservation number of CGMCC No.35195. According to the application, a newly found bactrian camel clostridium perfringens strain is used as an antigen. The 1059 ST type clostridium perfringens are separated from intestinal tracts of young bactrian camels for the first time, and the 1059 type (A type) and 675 type (D type) clostridium perfringens are inactivated to prepare the bivalent inactivated vaccine.

The invention belongs to the technical field of microorganisms, and discloses a clostridium perfringens bacteriophage CP-XHX1 and application thereof, the bacteriophage is preserved in the China Center for Type Culture Collection (CCTCC) on June 17, 2024, and the preservation number is CCTCC NO: M 20241270. The invention also provides a bactericide product prepared from the bacteriophage. The cracking rate of the clostridium perfringens A, E and G reaches 100%, the toxic and side effects are small, and the safety is high. The bacteriophage has a good lysis effect on clostridium perfringens, is strong in infection ability, can infect more host cells with a very small amount of viruses, and can replace antibiotics, so that the intestinal diseases of hosts are effectively treated.

The invention belongs to the technical field of microorganisms, and particularly relates to bacillus paralicheniformis CA10001 as well as application and a product thereof. The bacillus paralicheniformis CA10001 has been preserved in the China General Microbiological Culture Collection Center on February 22, 2024, and the preservation number of the bacillus paralicheniformis CA10001 is CGMCC No. 29876. The strain has relatively strong antibacterial ability, heat resistance, acid resistance and cholate resistance to clostridium perfringens, and can be used for improving feed quality and improving animal growth performance.

The application discloses a fermentation method for improving the tolerance of Clostridium aceticum to high-concentration CO gas and belongs to the technical field of microbial fermentation. In view of the substrate inhibition of high-concentration CO on Clostridium aceticum, the application proposes an asymmetric gas velocity regulation strategy of "over-regulation and slow increase". When the CO volume concentration is increased from C1 to C2, the inlet gas velocity is excessively decreased to V2=k*(C1 / C2)*V1, k=0.3-0.7; the low gas velocity is maintained for T1>=24 h to make the bacteria adapt to the high CO environment; and then the gas velocity is gradually increased to V3>=(C1 / C2)*V1 in stages. The method can make the Clostridium aceticum restore growth and metabolism within 2-3 days after the CO concentration is switched to 90%, the ethanol yield is increased by more than 18% compared with the 60% CO culture, and the method does not need genetic modification and can be directly adapted to the industrial tail gas with a CO content of 80-95%, thereby significantly improving the efficiency of high-concentration CO fermentation and the resource utilization value of the industrial tail gas.

The invention belongs to the technical field of genetic engineering, and particularly relates to recombinant lactobacillus plantarum for preventing and controlling chicken necrotic enteritis as well as a preparation method and application of the recombinant lactobacillus plantarum. The invention provides an oral vaccine vector capable of co-expressing various key virulence factor antigens (FimB, NetB, CnaA and FBA) of clostridium perfringens, and by fusing dendritic cell (DC) targeting molecules (nano antibody Phi74), the efficiency of recognizing and taking in the vaccine vector by full-time antigen presenting cells is remarkably improved, so that the immunogenicity is enhanced. When the recombinant lactobacillus is used for immunizing animals, mucosal immunity, cellular immunity and humoral immunity reactions can be induced, the immunity of organisms is comprehensively enhanced, and a safe and efficient oral immunization scheme suitable for large-scale breeding is established for treating chicken necrotic enteritis.

The invention relates to the technical field of microorganisms, in particular to a method for reducing the dosage of antibiotics for treating clostridium perfringens infection, a bactericidal composition, bacteriophage and application. According to the method, the clostridium perfringens bacteriophage RDP-CP-2310008 and one or more antibiotics are used in a combined mode, and the clostridium perfringens bacteriophage RDP-CP-2310008 and the one or more antibiotics are used in a combined mode. The clostridium perfringens bacteriophage RDP-CP-2310008 is preserved in the China General Microbiological Culture Collection Center on November 29, 2023, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.45778. The clostridium perfringens bacteriophage RDP-CP-2310008 can be used The bactericidal composition is prepared from the following effective components: the clostridium perfringens bacteriophage RDP-CP-2310008, and one or more antibiotics used for resisting the clostridium perfringens. The invention further discloses application of the clostridium perfringens phage RDP-CP-2310008 in preparation of a medicine for preventing and / or treating clostridium perfringens infection. The invention provides and verifies that the specific bacteriophage is combined with the antibiotics for the first time, so that the dosage of the antibiotics can be greatly reduced and can be up to 64 times, and a brand-new path is provided for solving the problem of abuse of the antibiotics in the breeding industry.

The application discloses a Clostridium perfringens Mbp gene and application thereof, and the nucleotide sequence of the gene is shown as SEQ ID NO. 3. The application extracts the whole genome from a virulent strain of Clostridium perfringens, designs primers to amplify the Mbp gene, and uses a prokaryotic expression method to prepare a recombinant Mbp protein. The immunoprotective effect is evaluated by using an animal experiment, and it is found for the first time that the Clostridium perfringens protein Mbp has good immunoreactivity and can significantly reduce the clinical symptoms caused by Clostridium perfringens. The Clostridium perfringens protein Mbp provided by the application has the potential to be used as a Clostridium perfringens subunit vaccine.

This invention discloses a strain of *Bacillus belyceae* with broad-spectrum antibacterial activity and its application in the prevention and treatment of necrotic enteritis in poultry. The *Bacillus belyceae* strain provided by this invention (… Bacillus from Velez The genome of strain GDG25CB056 is approximately 3.91 Mb in size, contains no virulence factors, and is rich in gene clusters encoding non-ribosomal peptides and polyketide synthases. Studies have confirmed that this strain exhibits significant growth advantages, strong tolerance to high temperatures, gastric acid, and bile salts, which facilitates intestinal colonization. It can produce siderophores and various enzymes, and has overcome the technical bottleneck of a narrow antibacterial spectrum, possessing broad-spectrum antibacterial activity, especially strong specific antagonistic activity against Clostridium perfringens. In vivo experiments have shown that this strain can significantly reduce the Clostridium perfringens load in the cecum of chicks with necrotizing enterocolitis, alleviate intestinal congestion and swelling, repair damaged intestinal villi, and enhance mucosal barrier function, providing a safe and efficient strain resource for the prevention and treatment of bacterial enteric diseases.

According to the present invention, provided is a Clostridium perfringens sporulation inhibitor that contains at least one inorganic compound at such a concentration as to cause the precipitation of C. perfringens in vivo, wherein the inorganic compound is a salt of at least one selected from the group consisting of K, Na, Mg, Ca and Fe and the inorganic compound is coated with a protective layer containing a hardened vegetable oil.

The invention discloses a method for quantitatively analyzing the content of alpha2-3 acetylneuraminic acid in glycoprotein, which comprises the following steps: firstly, treating a sample containing glycoprotein by using streptococcus pneumoniae acetylneuraminidase, and continuously treating the sample containing glycoprotein by using clostridium perfringens acetylneuraminidase in the same solution; centrifugally separating and taking a separating solution containing two acetylneuraminic acid products outside the centrifugal tube; and detecting and collecting two hydrolysates 2, 7-dehydrated acetylneuraminic acid and the signal intensity of acetylneuraminic acid in a negative ion mode, and calculating the percentage content of alpha2-3 linked acetylneuraminic acid by using a formula. According to the method, the sensitivity of quantitative analysis of alpha2-3 acetylneuraminic acid can be improved, and the time consumption of detection and analysis is reduced.

This invention relates to the field of Clostridium perfringens antigen technology, and particularly to a Clostridium perfringens α-toxin-ferritin nanoparticle antigen, its preparation method, and its application. The Clostridium perfringens α-toxin-ferritin nanoparticle antigen is assembled from αm2ST protein and FeSC protein. The αm2ST protein is expressed using an α-protein mutant expression plasmid, and the FeSC protein is expressed using a ferritin expression plasmid. The nucleotide sequence of the α-protein mutant expression plasmid is shown in SEQ ID NO: 1, and the nucleotide sequence of the ferritin expression plasmid is shown in SEQ ID NO: 2. The Clostridium perfringens α-toxin-ferritin nanoparticle antigen provided by this invention can effectively stimulate humoral and cellular immunity, providing a new approach for the development of Clostridium perfringens subunit vaccines.

The present application relates to a high-enzyme-activity protease producing bacillus natto FMN-1 with preservation number of CGMCC No.20659, and relates to the enzyme produced by the strain and the preparation method of the enzyme, and relates to a functional feed additive for preventing and treating avian necrotic enteritis of the strain and the enzyme, and relates to the preparation method of the additive, belonging to the technical field of poultry feed and feed additive. The weight fraction composition is as follows: 20-35 parts of traditional Chinese medicine enzymolysis mixture, 4-9 parts of bacillus natto, 4-10 parts of vitamin C, 4-10 parts of vitamin E, and 40-60 parts of talc. The feed digestion rate, daily weight gain of poultry can be improved, and the feed conversion ratio can be reduced. Taking broiler as an example, the daily weight gain is between 1.37% and 2.48%, and the feed conversion ratio is between 1.64 and 1.67. The immune function of poultry is improved, the disease resistance is enhanced, and the avian necrotic enteritis caused by clostridium perfringens is effectively prevented and treated.

This invention belongs to the field of microbial technology, and relates to a *Pediococcus pentosacchari* strain derived from geese, its isolation and screening method, and its application. The *Pediococcus pentosacchari* strain is *Pediococcus pentosacchari*. Pediococcus pentosaceus L2, deposited at the Guangdong Provincial Microbial Culture Collection Center, accession number GDMCC No:67207. This invention, *Pediococcus pentosaceus* L2, was isolated and screened from the cecum of healthy Magang geese. Its source is reliable and readily available, possessing safety and probiotic properties. It exhibits good antibacterial activity against *Clostridium perfringens*, demonstrating excellent probiotic potential for application in feed additives, probiotic preparations, and medications for treating geese infected with *Clostridium perfringens*.

The invention discloses a nucleic acid aptamer specifically bound with clostridium perfringens. A nucleotide sequence of the nucleic acid aptamer comprises a nucleotide sequence as shown in SEQ ID NO: 1. According to the nucleic acid aptamer specifically bound with clostridium perfringens, the dissociation constant Kd of binding with the clostridium perfringens is 66.91 + / -22.02 nM, and the aptamer only has high affinity to the clostridium perfringens and has no affinity to other bacteria, so that the aptamer has high specificity in binding with the clostridium perfringens, and therefore, the nucleic acid aptamer specifically bound with the clostridium perfringens can be applied to the field of biosynthesis of the clostridium perfringens. The aptamer provided by the invention has strong affinity and high specificity to the clostridium perfringens, and can realize efficient and rapid detection of the clostridium perfringens by taking the aptamer as a recognition element, thereby providing a new method for on-site rapid monitoring of supervision departments.